title: Effect of formulation design and freeze-drying on properties of fluconazole multilamellar liposomes.
abstract: Fluconazole-entrapped multilamellar liposomes were prepared using the thin-film hydration method. The effects of cholesterol molar ratio, charge-inducing agents, and α-tocopherol acetate on encapsulation efficiency values and in vitro drug release of multilamellar liposomes were studied. Freeze-dried liposomal products were prepared with or without cryoprotectants. Results showed that incorporation of stearylamine resulted in an increased entrapment of fluconazole, whereas incorporation of dicetyl phosphate decreased the drug entrapment efficiency. The incorporation of α-tocopherol acetate into fluconazole multilamellar liposomes resulted in the increase of entrapment efficiency of fluconazole liposomes. In vitro release studies revealed that incorporation of cholesterol into multilamellar liposomal formulations decreased drug permeability from formulations. Positively charged fluconazole multilamellar liposomes gave rise to a slow release rate compared to neutral liposomes whereas negatively charged fluconazole liposomes showed a rapid release rate. Physical stability studies showed that lyophilized cake of liposomes without cryoprotectants was compact and difficult to reconstitute compared to fluffy easily reconstituted cakes upon using cryoprotectants. Fluconazole retained in freeze-dried liposomes without cryoprotectants was 63.452% compared to 91.877% using three grams of trehalose as a cryoprotectant per gram lipid in positively charged multilamellar liposomes. Physical stability studies showed superior potentials of the lyophilized product after reconstitution in comparison with those of a solution product.
authors: Pharmaceutics Department, Faculty of Pharmacy, King Khalid University, Abha, Saudi Arabia.
authors: Ola H
authors: OH
authors: El-Nesr
authors: Soad A
authors: SA
authors: Yahiya
authors: Omaima N
authors: ON
authors: El-Gazayerly
keywords: Fluconazole; Freeze-drying; Multilamellar liposomes; Ophthalmic; Stability
references: Biochim Biophys Acta. 1992 Jan 31;1103(2):259-67
references: 1543711
references: Exp Eye Res. 2001 Feb;72(2):147-51
references: 11161730
references: Am J Ophthalmol. 2005 Sep;140(3):454-8
references: 16026751
references: J Microencapsul. 1992 Jul-Sep;9(3):317-27
references: 1403482
references: Drug Dev Ind Pharm. 2000 Sep;26(9):913-24
references: 10914315
references: Clin Microbiol Rev. 2000 Oct;13(4):662-85
references: 11023963
references: J Microencapsul. 1998 Jul-Aug;15(4):485-94
references: 9651870
references: Br J Ophthalmol. 1990 Jan;74(1):40-2
references: 2306443
references: Acta Ophthalmol. 2008 Aug;86(5):525-32
references: 18752527
references: J Microencapsul. 1995 Sep-Oct;12(5):525-35
references: 8544096
references: Drug Dev Ind Pharm. 2000 Mar;26(3):313-21
references: 10738648
references: J Liposome Res. 2009;19(3):197-206
references: 19259886
references: J Microencapsul. 1998 Jul-Aug;15(4):473-83
references: 9651869
references: Acta Ophthalmol (Copenh). 1986 Jun;64(3):298-301
references: 3751519
references: J Microencapsul. 2001 Mar-Apr;18(2):211-21
references: 11253938
references: Antimicrob Agents Chemother. 1994 Jun;38(6):1422-4
references: 8092849
references: Biophys J. 1996 Apr;70(4):1769-76
references: 8785336
references: Cornea. 1997 Jan;16(1):64-71
references: 8985636
references: J Microencapsul. 1999 May-Jun;16(3):357-67
references: 10340220
references: Arch Biochem Biophys. 1985 Oct;242(1):240-7
references: 4051504
references: J Microencapsul. 1993 Apr-Jun;10(2):229-36
references: 8331496
references: Acta Ophthalmol. 2010 Dec;88(8):901-4
references: 19681761